Isaac Ro is a Partner at Catalio Capital Management, LP. He currently serves on the Boards of Anagenex, Pink Dx., and PrognomiQ.
He previously served as Executive Chairman of Haystack Oncology and led the sale of the company to Quest Diagnostics for $450 million.
Prior to joining Catalio, he was the Chief Financial Officer of Sema4 (NASDAQ: WGS) where he took the company public in 2021 at a valuation of $2 billion and subsequently led the acquisition of GeneDx. Prior to Sema4, Isaac served as the Chief Financial Officer of Thrive Earlier Detection where he helped launch the company and raise $367 million in venture funding. He subsequently led the sale of Thrive to Exact Sciences in 2020 for $2.1 billion.
From 2010 to 2019, Isaac led the U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs where he was top ranked by FT StarMine for stock picking and earnings accuracy. Prior to Goldman Sachs, he held the same role at Leerink Partners where he was named Best Up and Comer by Institutional Investor and was a Healthcare investor at Independence Investments.
Isaac earned his B.A. in History and was Pre-Med at Middlebury College.